2019 U.S.-Booked Air Volume: $53 million
Consolidated U.S. TMC: BCD
Global revenue for the pharmaceutical and biopharmaceutical company AstraZeneca increased 10 percent to $24.3 billion in 2019, at the end of which it had 70,600 employees. Product sales grew fastest in emerging markets, up 35 percent, and the U.S., up 33 percent. BTN estimates the value of U.S.-originating air travel climbed from $47 million to $53 million. In January 2020, AstraZeneca declared its intention to produce zero emissions from its global operations by 2025 and make its entire value chain carbon-negative by 2030, although it did not detail specific plans for business travel.